Peginesatide in Patients with Anemia Undergoing Hemodialysis

• Published in: The New England journal of medicine Vol. 368; no. 4; pp. 307 - 319
• Main Authors: Fishbane, Steven, Schiller, Brigitte, Locatelli, Francesco, Covic, Adrian C, Provenzano, Robert, Wiecek, Andrzej, Levin, Nathan W, Kaplan, Mark, Macdougall, Iain C, Francisco, Carol, Mayo, Martha R, Polu, Krishna R, Duliege, Anne-Marie, Besarab, Anatole
• Format: Journal Article
• Language: English
• Published: Waltham, MA Massachusetts Medical Society 24.01.2013
• Subjects: Aged; Anemia; Anemia - drug therapy; Anemia - etiology; Anemias. Hemoglobinopathies; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Antibodies - blood; Biological and medical sciences; Disease-Free Survival; Diseases of red blood cells; Drug Administration Schedule; Emergency and intensive care: renal failure. Dialysis management; Erythropoietin - adverse effects; Erythropoietin - therapeutic use; Female; General aspects; Heart attacks; Hematinics - adverse effects; Hematinics - therapeutic use; Hematologic and hematopoietic diseases; Hemoglobins - analysis; Humans; Intensive care medicine; Kaplan-Meier Estimate; Male; Medical sciences; Middle Aged; Patient safety; Peptides - adverse effects; Peptides - immunology; Peptides - therapeutic use; Renal Dialysis - adverse effects; Renal Insufficiency, Chronic - blood; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - mortality; Renal Insufficiency, Chronic - therapy; United States > US; Human; Medicine; Extrarenal dialysis; Anemia; Hemodialysis; Patient; Hemopathy
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1203165

In two randomized, controlled studies involving patients undergoing long-term hemodialysis, peginesatide, a synthetic peptide-based erythropoiesis-stimulating agent, was compared with epoetin for the treatment of anemia. The two agents were similarly effective. Partial correction of anemia with erythropoiesis-stimulating agents (ESAs) is a cornerstone of therapy for patients undergoing dialysis, because these agents increase hemoglobin levels, which results in a reduction in blood-transfusion rates. 1 , 2 Partial correction of anemia has also been reported to enhance quality of life. 3 More intensive treatment with ESAs, targeting near-normal hemoglobin levels, in the Normal Hematocrit Study (NHS), 4 the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) study, 5 and the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) 6 further reduced the need for blood transfusions, but an increased risk of adverse events was reported (the composite . . .